Provention Bio Inc

NASDAQ:PRVB   3:59:55 PM EDT
12.57
-0.61 (-4.63%)
Regulatory, Other Pre-Announcement

Provention Bio Files Clinical Module For Teplizumab For Delay Or Prevention Of Clinical Type 1 Diabetes In At-Risk Individuals

Published: 09/30/2020 20:30 GMT
Provention Bio Inc (PRVB) - Provention Bio Files Clinical Module for Teplizumab for the Delay Or Prevention of Clinical Type 1 Diabetes in At-risk Individuals.
Provention Bio Inc - Announced Submission of Clinical Module of Biologic License Application for Teplizumab (prv-031).
Provention Bio Inc - Expects to Submit Final Modules for Teplizumab Including Chemistry, Manufacturing and Controls Module in Q4 2020.